<qa>  What was the maximum randomized treatment duration planned?A maximum randomized treatment duration of 168 weeks was planned. Since subjects with decompensated liver disease were enrolled into this study, it was necessary to provide early intervention strategies if profound viral suppression was not expeditiously achieved. For this reason, subjects with a decrease in plasma HBV DNA from baseline of 2 log_10 copiesmL and plasma HBV DNA 10,000 copiesmL or plasma HBV DNA 1,000 copiesmL for subjects who entered the study with HBV DNA 10,000 copiesmL at Week 8 had the option to start open-label FTCTDF and continue in the study. Subjects with a virologic breakthrough or who had plasma HBV DNA levels remaining 400 copiesmL confirmed at or after 24 weeks of treatment could have been unblinded at the investigators discretion for selection of alternative anti-HBV therapy that may have included open-label FTCTDF. If study drug was permanently discontinued, immediate initiation of another anti-HBV regimen was strongly recommended. 